A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid
A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid
复制标题
获得性反应性穿孔性皮肤病样大疱性类天疱疮的新临床变型
DOI:
10.1111/bjd.17146
复制
发表时间:
2018
影响因子:
10.3
通讯作者:
Kiritsi D.
中科院分区:
文献类型:
--
作者:
Schauer F.;Kern J.S.;Virtic O.;Technau-Hafsi K.;Meiss F.;Thoma K.;Athanasiou I.;Sitaru C.;Di Zenzo G.;Izumi K.;Nishie W.;Shimizu H.;Bruckner-Tuderman L.;Kiritsi D.
DEAR EDITOR, Bullous pemphigoid (BP) is a blistering disorder associated with circulating autoantibodies against BP180/collagen XVII. As part of a prodromal stage, patients might present with eczematous lesions or erythematous papules and prurigoor urticaria-like erythema without any blistering. 1 Recent studies described four patients with clinical features resembling acquired reactive perforating dermatosis (ARPD) coexisting with BP. 2, 3 They initially presented with papules and nodules with a central keratotic plaque, with diabetes mellitus (DM) and haemodialysis thought to be causative. They developed point blisters only later, and BP180 autoantibodies were found to bind at the dermoepidermal junction zone (DEJZ). We here describe five previously unreported patients whose symptoms clinically and histologically resembled ARPD with simultaneous BP diagnosis. All patients were over 70 years of age with several concomitant disorders, and all except patient 1 were female. They all had hypertension; patients 3 and 4 also had atrial fibrillation, whereas patients 1 and 3 also had type II DM with signs of diabetic nephropathy. Patient 2 had a history of breast cancer in remission, 11 years prior. We found elevated IgE levels and an elevated blood eosinophil count. Patients 1–4 presented with a history of sudden severe itch and generalized papules and nodules with a central keratotic plaque without any blisters (Fig. 1b). At presentation, patient 5 had characteristic BP with large urticarial plaques and blisters covering large parts of her integument, which had developed 245 months earlier (Fig. 1b). After the diagnosis of BP, she received topical treatment with clobetasol propionate ointment, systemic prednisolone and mycophenolate mofetil. She showed quick treatment response with reduced itch and healing of lesions. Six weeks later she presented again, now with the ARPD picture of papular lesions with central keratotic plugs on her legs, back and upper arms (Fig. 1b). In the biopsies taken from the papules and nodules in patients 1–4, the histopathology showed a cup-shaped invagination of the epidermis filled with necrotic debris and vertically penetrating collagen bundles between dermis and epidermis with a dermal neutrophilic infiltrate (Fig. 1c). This represents the histopathological hallmark of reactive perforating collagenosis (RPC). 4 Solely in the skin biopsy of patient 5, with blistering at initial presentation, subepidermal skin cleavage with dense eosinophilic infiltrate and dermal oedema was found. Direct immunofluorescence was performed in all cases at first presentation. It showed the typical linear deposition of IgG and C3c at the DEJZ. The indirect immunofluorescence showed IgG deposition on the blister roof, also in all patients (Fig. 1a). The presence of autoantibodies against the full-length form of BP180 has recently been linked to a noninflammatory BP phenotype, accompanied by scant lesional eosinophilic infiltration. 5 Enzyme-linked immunosorbent assay recognizing the NC16A domain did not detect BP180 IgG autoantibodies in patients 1, 3 and 4, but patients 1 and 3 had autoantibodies against the full-length BP180 (data available on request). Patients 2 and 4 also had BP230 antibodies. IgE autoantibodies are associated with increased BP severity. We analysed the sera for IgE autoantibodies to BP180 and BP230 and found lowlevel BP230 IgE autoantibodies in cases 2 and 4, while case 5 had low-level BP180 and BP230 IgE autoantibodies. To investigate the pathogenic potential of autoantibodies in these patients, we have used a previously described ex vivo assay (figure available on request). 6 The BP treatment …